One-Year Clinical Outcomes Following Electroconvulsive Therapy for Patients with Schizophrenia: A Nationwide Health Insurance Data-Based Study

References

• Ahmed S, Khan AM, Mekala HM, et al. Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: a comparative meta-analysis. Heliyon. 2017;3(11):e00429. doi:10.1016/j.heliyon.2017.e00429
   PubMed Web of Science ®Google Scholar
• Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015;172(1):52–58. doi:10.1176/appi.ajp.2014.13060787
   PubMed Web of Science ®Google Scholar
• Grover S, Sahoo S, Rabha A, Koirala R. ECT in schizophrenia: a review of the evidence. Acta Neuropsychiatr. 2019;31(3):115–127. doi:10.1017/neu.2018.32
   PubMed Web of Science ®Google Scholar
• Swartz CM. Electroconvulsive and Neuromodulation Therapies. Cambridge University Press; 2009.
   Google Scholar
• Slade EP, Jahn DR, Regenold WT, Case BG. Association of electroconvulsive therapy with psychiatric readmissions in US hospitals. JAMA Psychiatry. 2017;74(8):798–804. doi:10.1001/jamapsychiatry.2017.1378
   PubMed Web of Science ®Google Scholar
• Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283–344. doi:10.1002/brb3.37
   PubMed Web of Science ®Google Scholar
• Xiang YT, Ungvari GS, Correll CU, et al. Use of electroconvulsive therapy for Asian patients with schizophrenia (2001–2009): trends and correlates. Psychiatry Clin Neurosci. 2015;69(8):489–496. doi:10.1111/pcn.12283
   PubMed Web of Science ®Google Scholar
• Osler M, Rozing MP, Christensen GT, Andersen PK, Jørgensen MB. Electroconvulsive therapy and risk of dementia in patients with affective disorders: a cohort study. Lancet Psychiat. 2018;5(4):348–356. doi:10.1016/s2215-0366(18)30056-7
   Web of Science ®Google Scholar
• Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. doi:10.1016/j.biopsych.2010.06.009
   PubMed Web of Science ®Google Scholar
• Baghai TC, Möller H-J. Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci. 2008;10(1):105–117. doi:10.31887/DCNS.2008.10.1/tcbaghai
   PubMedGoogle Scholar
• Youssef NA, McCall WV. Is conduct of research in electroconvulsive therapy ethical? J Psychol Neuropsychiatr Disord Brain Stimul. 2016;1(1):105. doi:10.19104/jpbd.2016.105
   Google Scholar
• Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718–728. doi:10.3346/jkms.2017.32.5.718
   PubMed Web of Science ®Google Scholar
• Joo SW, Kim H, Jo YT, Choi YJ, Ahn S, Lee J. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study. Psychol Med. 2021;1–8. doi:10.1017/s0033291721001379
   Web of Science ®Google Scholar
• Joo SW, Shon S-H, Choi G, Koh M, Cho SW, Lee J. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: a nationwide population-based study. Eur Neuropsychopharmacol. 2019;29(9):1051–1060. doi:10.1016/j.euroneuro.2019.07.138
   PubMed Web of Science ®Google Scholar
• George A, Keepers MD, Laura J, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.177901
   Web of Science ®Google Scholar
• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8(1):5. doi:10.1038/s41537-021-00192-x
   Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686–693. doi:10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiat. 2019;76(5):499–507. doi:10.1001/jamapsychiatry.2018.4320
   PubMed Web of Science ®Google Scholar
• Laidi C, Prigent A, Plas A, et al. Factors associated with direct health care costs in schizophrenia: results from the FACE-SZ French dataset. Eur Neuropsychopharmacol. 2018;28(1):24–36. doi:10.1016/j.euroneuro.2017.11.020
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373. doi:10.2147/ndt.S96649
   PubMed Web of Science ®Google Scholar
• Ha J, Cho S, Shin Y. Utilization of health insurance data in an environmental epidemiology. Environ Health Toxicol. 2015;30:e2015012. doi:10.5620/eht.e2015012
   Google Scholar
• Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res. 2020;215:8–16. doi:10.1016/j.schres.2019.09.013
   PubMed Web of Science ®Google Scholar
• Acosta FJ, Hernández JL, Pereira J, Herrera J, Rodríguez CJ. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74–82. doi:10.5498/wjp.v2.i5.74
   PubMedGoogle Scholar
• El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis. Front Neurosci. 2020;14:531763. doi:10.3389/fnins.2020.531763
   PubMed Web of Science ®Google Scholar
• Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018;17(1):12–23. doi:10.1002/wps.20508
   PubMed Web of Science ®Google Scholar
• Lin H-T, Liu S-K, Hsieh MH, et al. Impacts of electroconvulsive therapy on 1-year outcomes in patients with schizophrenia: a controlled, population-based mirror-image study. Schizophr Bull. 2017;44(4):798–806. doi:10.1093/schbul/sbx136
   Web of Science ®Google Scholar
• Kadakia A, Fan A, Marden J, et al. The economic burden of schizophrenia in the United States in 2019. CNS Spectr. 2022;27(2):227. doi:10.1017/S1092852922000207
   Google Scholar
• Zhang H, Sun Y, Zhang D, Zhang C, Chen G. Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China. Int J Ment Health Syst. 2018;12(1):72. doi:10.1186/s13033-018-0251-x
   Web of Science ®Google Scholar
• Jo M, Kim HJ, Rim SJ, Lee MG, Kim CE, Park S. The cost-of-illness trend of schizophrenia in South Korea from 2006 to 2016. PLoS One. 2020;15(7):e0235736. doi:10.1371/journal.pone.0235736
   Web of Science ®Google Scholar
• Thirthalli J, Naik SS, Kunigiri G. Frequency and duration of course of ECT sessions: an appraisal of recent evidence. Indian J Psychol Med. 2020;42(3):207–218. doi:10.4103/IJPSYM.IJPSYM_410_19
   PubMedGoogle Scholar